A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination With Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

- During dose escalation, subjects with advanced solid tumors (except for primary CNS
metastases) that have progressed following at least one standard regimen

- During cohort expansion, subjects with non small cell lung cancer, melanoma, renal
cell carcinoma, melanoma, colorectal, and ovarian cancer that have received at least
one and no more than 5 prior treatment regimens

- Subjects must have measurable disease

- Subject must consent to provide previously collected tumor tissue

- Women and men ≥ 18 years of age with performance status of 0 or 1

- At least 4 weeks since any previous treatment for cancer

Exclusion Criteria:

- Prior therapy with an immune cell modulating antibody except for anti-Cytotoxic T
Lymphocyte Antigen 4 (CTLA4)

- Active or chronic autoimmune diseases

- Uncontrolled or significant cardiovascular disease

- Chronic hepatitis

- Active infection

- Active Central nervous system (CNS) metastases